Mosunetuzumab - Genentech
Alternative Names: Anti-CD20/CD3 T-cell dependent bispecific antibody; BTCT 4465A; CD20-TBD; CD20xCD3 T-cell engaging bispecific antibody; Lunsumio; mosunetuzumab-axgb; RG7828; RO7030816Latest Information Update: 28 Jul 2024
At a glance
- Originator Genentech
- Developer Genentech; Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Follicular lymphoma
- Phase III Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Phase II Marginal zone B-cell lymphoma
- Phase I/II Chronic lymphocytic leukaemia
- Phase I B-cell lymphoma; Systemic lupus erythematosus
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Follicular lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 13 Feb 2024 Efficacy and adverse event data from a phase I expanded cohort trial in Follicular lymphoma released by Chugai Pharamceuticals
- 09 Feb 2024 Chugai Pharamceuticals completes a phase I expanded cohort trial in Follicular lymphoma (Second-line therapy or greater, Refractory disease) in Japan (JapicCTI-183857)